MAP4K4 Antibody (pThr187),StressMarq Biosciences Inc.,SPC-994D

Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4), particularly in its phosphorylated form at threonine 187 (pThr187), is emerging as a key upstream regulator of stress-responsive signaling pathways in the nervous system. MAP4K4 activates the JNK (c-Jun N-terminal kinase) pathway, a critical mediator of neuronal apoptosis, inflammation, and synaptic remodeling—processes commonly disrupted in neurodegenerative diseases. Phosphorylation of MAP4K4 at Thr187 enhances its kinase activity, facilitating downstream phosphorylation of targets such as SMAD1 at Thr322. This interaction links MAP4K4 to TGF-β signaling, which plays a dual role in neuroprotection and neurodegeneration depending on cellular context. Dysregulated MAP4K4 signaling has been implicated in neuroinflammatory responses, oxidative stress, and glial activation, contributing to the progression of disorders such as Alzheimer’s disease, Parkinson’s disease, and ALS. MAP4K4 also influences cytoskeletal dynamics and blood-brain barrier integrity, suggesting broader roles in neuronal structure and vascular health. Its activation under pathological conditions makes MAP4K4 (pThr187) a promising biomarker and therapeutic target for modulating stress-induced neurodegenerative cascades. As neuroscience increasingly focuses on kinase-driven signaling networks, MAP4K4 stands out as a critical molecular switch linking extracellular stress to intracellular degeneration. Targeting its phosphorylation state may offer novel strategies for halting or reversing neurodegenerative progression.

MAP4K4, HGK, HPK/GCK like kinase, Hepatocyte progenitor kinase like/germinal center kinase like kinase, KIAA0687, M4K4_HUMAN, MAPK/ERK kinase kinase kinase 4, MEK kinase kinase 4, MEKKK 4, Mitogen activated protein kinase kinase kinase kinase 4, Nck interacting kinase, NIK